Idt Australia Limited
IDT.ASXHealth Care
Supply of products and provision of research and development and other technical services for the pharmaceutical and allied industries.
Market Data
$0.035
-0.1%$17.5M
-100000.0x
$-0.014
0.00%
-0.5%
Latest Earnings
1HFY26 Appendix 4D and Half Year Report
18 February 2026
IDT Australia's loss narrowed significantly by 59.5% to $1.3 million in H1FY26, the strongest profitability metrics since its strategic transformation began over two years ago. While revenue declined 7% to $9.8 million, improved operational efficiency drove the better result, with positive operating cash flow of $1.6 million and strengthened cash position to $1.9 million. Key points: Loss narrowed significantly by 59.5% to $1.3 million, strongest profitability metrics since strategic transformation; Strong cash flow turnaround with $1.6 million operating cash inflows vs $5.2 million outflow in prior year; API Manufacturing grew strongly by 191.4% to $3 million, Specialty Orals up 26% to $2.5 million
Recent Announcements
Upgrade to FY26 Guidance
IDT Australia Limited (ASX: IDT) upgraded its FY26 guidance, expecting revenue from three verticals to reach $16.8M (+16.5% YoY) and EBITDA to improve significantly to -$943K versus -$6.3M in FY25, driven by strong demand for its drug manufacturing services and cost savings ahead of target. The company also received two prestigious RNA manufacturing awards from IMAPAC, recognizing its leadership in RNA therapeutics.
March Quarter Update & Positive FY26 Guidance
IDT Australia Limited (ASX: IDT) reported that FY26 EBITDA losses are forecast to narrow materially to $1.5M-$2M (a 68-76% improvement on FY25's $6.3M loss) with revenue expected between $15M-$16M, supported by Sanofi's Preferred Vendor designation, favorable US policy shifts for psychedelics/cannabis, recommissioned facilities, and a strategic partnership with Fierce Pharma to access global pharmaceutical markets.
1HFY26 Appendix 4D and Half Year Report
IDT Australia's loss narrowed significantly by 59.5% to $1.3 million in H1FY26, the strongest profitability metrics since its strategic transformation began over two years ago. While revenue declined 7% to $9.8 million, improved operational efficiency drove the better result, with positive operating cash flow of $1.6 million and strengthened cash position to $1.9 million. Key points: Loss narrowed significantly by 59.5% to $1.3 million, strongest profitability metrics since strategic transformation; Strong cash flow turnaround with $1.6 million operating cash inflows vs $5.2 million outflow in prior year; API Manufacturing grew strongly by 191.4% to $3 million, Specialty Orals up 26% to $2.5 million
Get real-time alerts for IDT
Receive AI-powered earnings summaries and instant notifications when Idt Australia Limited releases results.
Register Free